unknown
Stage
1
Investors
About
FABENTECH develops and produces emergency treatments to counteract bioterrorism risks and priority emerging infectious diseases by using a proprietary platform to generate purified polyclonal antibody fragments that neutralize viruses and toxins.
Explore FABENTECH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.